Publications by authors named "Ayumi Emoto"
Article Synopsis
- Apremilast has been shown to be safe and effective for treating psoriatic diseases, including plaque psoriasis (PsO) and psoriatic arthritis (PsA), in Japanese patients based on post-marketing surveillance conducted after its approval in 2016.
- The study, which involved over 1,000 patients observed for 12 months, reported that adverse reactions (ARs) occurred in about 29.4% of patients, with gastrointestinal issues being the most common; serious ARs were rare and no serious infections or fatalities were reported.
- Effectiveness results indicated substantial improvement in PsO patients, with 90.9% achieving global improvement after 6 months and 93.8% after 12
